Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting

Why It Matters

The presentations showcase Kelun‑Biotech’s expanding global oncology portfolio, positioning its ADC and targeted therapies for wider regulatory approval and partnership opportunities that could reshape treatment standards in NSCLC and other solid tumors.

Key Takeaways

• Sac‑TMT plus pembrolizumab shows improved outcomes vs pembrolizumab alone
• Lunbotinib receives FDA clearance for Phase II, pending Chinese NDA review
• SKB500 first‑in‑human data highlight safety across multiple solid tumors
• Kelun’s ADC platform gains visibility at ASCO, attracting global collaborators

Pulse Analysis

The American Society of Clinical Oncology’s 2026 meeting in Chicago serves as a barometer for emerging cancer therapeutics, and Kelun‑Biotech’s three oral presentations signal the company’s ambition to compete on a global stage. By leveraging its proprietary OptiDC™ platform, Kelun is adding depth to the rapidly expanding ADC market, which analysts project to exceed $30 billion by 2030. The visibility at ASCO not only validates its scientific pipeline but also attracts potential licensing partners eager to diversify their oncology portfolios.

Sac‑TMT, Kelun’s flagship TROP2‑directed ADC, is being evaluated in a head‑to‑head Phase III trial against pembrolizumab monotherapy in PD‑L1‑positive NSCLC. The combination leverages a bifunctional linker that delivers a topoisomerase‑I payload with a high drug‑to‑antibody ratio, aiming for both on‑target cytotoxicity and a bystander effect. Kelun’s exclusive licensing deal with MSD for all markets outside Greater China underscores the drug’s commercial potential; six Chinese breakthrough therapy designations and inclusion on the national reimbursement list further accelerate market uptake once global approvals are secured.

Beyond sac‑TMT, Kelun’s pipeline includes lunbotinib, a next‑generation selective RET inhibitor that has cleared the FDA’s hurdle to enter Phase II trials in the United States and Europe, while a Chinese NDA is under review. Concurrently, the first‑in‑human data for SKB500, another ADC candidate, demonstrate a manageable safety profile across diverse solid tumors, positioning it for combination strategies with immunotherapy. Together, these assets diversify Kelun’s revenue streams and enhance its bargaining power in future collaborations, suggesting a trajectory toward becoming a notable player in the international oncology arena.